Physician profile
Mark Sides
NPI 1861879348
$871.76
in general payments reported to CMS, 2019-2025
19 companies · $227 in 2025
The $227 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $150 · 2022: $94.26 · 2023: $256 · 2024: $144 · 2025: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $628.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $627.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $176.12 | 2023-2025 | Enhertu, Datroway, Vanflyta |
| Novocure INC. | $150.00 | 2021 | |
| Merck Sharp & Dohme LLC | $76.34 | 2022-2023 | Keytruda |
| Array Biopharma INC | $67.42 | 2024-2025 | Lorbrena, Braftovi, Mektovi |
| Astrazeneca Pharmaceuticals Lp | $54.92 | 2023-2025 | |
| Astellas Pharma US INC | $46.58 | 2023-2024 | Xtandi |
| Regeneron Healthcare Solutions, INC. | $42.13 | 2023 | Libtayo |
| Celgene Corporation | $35.14 | 2022-2025 | Opdivo |
| Jazz Pharmaceuticals INC. | $34.94 | 2022-2023 | Zepzelca |
| Novartis Pharmaceuticals Corporation | $24.89 | 2023 | |
| Eisai INC. | $24.77 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $23.30 | 2023 | Imbruvica |
| Pfizer INC. | $22.86 | 2025 | |
| Incyte Corporation | $22.15 | 2023 | Jakafi |
| E.R. Squibb & Sons, L.L.C. | $19.74 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $19.56 | 2023 | Alunbrig |
| Glaxosmithkline, LLC. | $17.49 | 2025 | Zejula, Jemperli |
| Blueprint Medicines Corporation | $13.41 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Sides listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.